NCT03380871View on ClinicalTrials.gov

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

October 31, 2019

Study Completion Date

February 5, 2021

Conditions

Carcinoma, Non-Small-Cell LungLung CancerNonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

BIOLOGICAL

NEO-PV-01

Personal Cancer Vaccine

BIOLOGICAL

Pembrolizumab

monoclonal antibody against PDL1

OTHER

Adjuvant

immune adjuvant

DRUG

Carboplatin

chemotherapy

DRUG

Pemetrexed

chemotherapy

Trial Locations (5)

37203

Sarah Cannon Research Institute, Nashville

63130

Washington University in St. Louis, St Louis

90404

University of California - Los Angeles, Santa Monica

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

BioNTech US Inc.

INDUSTRY

NCT03380871 - A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | Biotech Hunter | Biotech Hunter